CD86 Is a Selective CD28 Ligand Supporting FoxP3+ Regulatory T Cell Homeostasis in the Presence of High Levels of CTLA-4.
CD28
CD80
CD86
CTLA-4
costimulation
homeostasis
regulatory T cells
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
28
08
2020
accepted:
04
11
2020
entrez:
28
12
2020
pubmed:
29
12
2020
medline:
17
6
2021
Statut:
epublish
Résumé
CD80 and CD86 are expressed on antigen presenting cells and are required to engage their shared receptor, CD28, for the costimulation of CD4 T cells. It is unclear why two stimulatory ligands with overlapping roles have evolved. CD80 and CD86 also bind the regulatory molecule CTLA-4. We explored the role of CD80 and CD86 in the homeostasis and proliferation of CD4+FoxP3+ regulatory T cells (Treg), which constitutively express high levels of CTLA-4 yet are critically dependent upon CD28 signals. We observed that CD86 was the dominant ligand for Treg proliferation, survival, and maintenance of a regulatory phenotype, with higher expression of CTLA-4, ICOS, and OX40. We also explored whether CD80-CD28 interactions were specifically compromised by CTLA-4 and found that antibody blockade, clinical deficiency of CTLA-4 and CRISPR-Cas9 deletion of CTLA-4 all improved Treg survival following CD80 stimulation. Taken together, our data suggest that CD86 is the dominant costimulatory ligand for Treg homeostasis, despite its lower affinity for CD28, because CD80-CD28 interactions are selectively impaired by the high levels of CTLA-4. These data suggest a cell intrinsic role for CTLA-4 in regulating CD28 costimulation by direct competition for CD80, and indicate that that CD80 and CD86 have discrete roles in CD28 costimulation of CD4 T cells in the presence of high levels of CTLA-4.
Identifiants
pubmed: 33363541
doi: 10.3389/fimmu.2020.600000
pmc: PMC7753196
doi:
Substances chimiques
B7-2 Antigen
0
CD28 Antigens
0
CD86 protein, human
0
CTLA-4 Antigen
0
CTLA4 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
600000Subventions
Organisme : Versus Arthritis
ID : 21738
Pays : United Kingdom
Organisme : Arthritis Research UK
ID : 21147
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 110297/Z/15/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 204798/Z/16/Z
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 20478/Z/16
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/M009203/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N001435/1
Pays : United Kingdom
Informations de copyright
Copyright © 2020 Halliday, Williams, Kennedy, Waters, Pesenacker, Soskic, Hinze, Hou, Rowshanravan, Janman, Walker and Sansom.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Immunol. 2003 Oct 1;171(7):3348-52
pubmed: 14500627
Immunity. 2016 May 17;44(5):973-88
pubmed: 27192564
Nat Rev Immunol. 2011 Nov 25;11(12):852-63
pubmed: 22116087
Nat Med. 2014 Dec;20(12):1410-1416
pubmed: 25329329
Nat Methods. 2006 Dec;3(12):1001-6
pubmed: 17086179
Nature. 1992 Apr 16;356(6370):607-9
pubmed: 1313950
Nat Immunol. 2005 Feb;6(2):152-62
pubmed: 15640801
J Exp Med. 1993 Dec 1;178(6):2185-92
pubmed: 7504059
Immunity. 2002 Aug;17(2):201-10
pubmed: 12196291
J Exp Med. 2015 Sep 21;212(10):1603-21
pubmed: 26371185
Eur J Immunol. 1997 Aug;27(8):1848-52
pubmed: 9295017
Eur J Immunol. 2013 Jan;43(1):188-93
pubmed: 23065717
Immunity. 2004 Sep;21(3):401-13
pubmed: 15357951
J Immunol. 2007 Dec 1;179(11):7924-31
pubmed: 18025240
J Exp Med. 1994 Nov 1;180(5):1841-7
pubmed: 7525840
J Immunol. 2001 Nov 15;167(10):5669-77
pubmed: 11698439
J Immunol. 2015 Mar 1;194(5):2148-59
pubmed: 25632005
J Exp Med. 2007 Sep 3;204(9):2103-14
pubmed: 17698588
Eur J Immunol. 2006 Jun;36(6):1413-22
pubmed: 16708397
Eur J Immunol. 2011 Feb;41(2):291-8
pubmed: 21267999
Proc Natl Acad Sci U S A. 2016 Apr 26;113(17):E2383-92
pubmed: 27071130
Mol Immunol. 2009 Jan;46(3):457-72
pubmed: 19081138
J Exp Med. 1994 Aug 1;180(2):631-40
pubmed: 7519245
J Immunol. 1995 Jan 1;154(1):97-105
pubmed: 7527824
Eur J Immunol. 1996 Jun;26(6):1273-7
pubmed: 8647204
Cytometry A. 2011 Feb;79(2):95-101
pubmed: 21265003
J Exp Med. 2000 Jul 17;192(2):295-302
pubmed: 10899916
Immunol Rev. 2006 Aug;212:131-48
pubmed: 16903911
J Clin Invest. 2013 Feb;123(2):580-93
pubmed: 23281398
Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11059-63
pubmed: 7504293
J Exp Med. 2005 Jul 4;202(1):33-45
pubmed: 15983066
J Immunol. 2012 Aug 1;189(3):1118-22
pubmed: 22753931
Immunity. 2000 Apr;12(4):431-40
pubmed: 10795741
J Immunol. 1997 Mar 15;158(6):2713-22
pubmed: 9058805
Blood. 2017 Mar 16;129(11):1458-1468
pubmed: 28159733
Genome Biol. 2005;6(6):223
pubmed: 15960813
J Immunol. 2009 Jan 1;182(1):274-82
pubmed: 19109158
Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11054-8
pubmed: 7504292
J Immunol. 1995 Aug 1;155(3):1151-64
pubmed: 7636184
Science. 1996 Jul 5;273(5271):104-6
pubmed: 8658175
Immunology. 1993 Aug;79(4):616-20
pubmed: 8406586
Eur J Immunol. 2000 Sep;30(9):2650-9
pubmed: 11009099
Immunity. 1997 Mar;6(3):303-13
pubmed: 9075931
Science. 2011 Apr 29;332(6029):600-3
pubmed: 21474713
J Exp Med. 2000 Jul 17;192(2):303-10
pubmed: 10899917